Depram25 mg

Depram is a tricyclic antidepressant (TCA) indicated for the following:

• Depression (established/FDA-approved use): Treatment of symptoms of depression, including endogenous depression, in adults. Clinical improvement may take 1-3 weeks.
• Nocturnal enuresis in children (established/FDA-approved use, short-term adjunct): As an adjunct in the treatment of nocturnal enuresis (bedwetting) in children aged 6 years and older, after organic causes (e.g. structural, infectious, or endocrine abnormalities) have been excluded. Not intended as sole or long-term therapy.
• Off-label uses (not FDA-approved, based on limited evidence/clinical practice): Chronic neuropathic pain, panic disorder, and attention-deficit/hyperactivity disorder (ADHD) in patients who have not responded to standard therapies. These uses require individualized physician judgment.

Boxed Warning

Depram and other antidepressants carry an FDA boxed warning for increased risk of suicidal thinking and behavior in children, adolescents, and young adults under 25 years of age, particularly during the early weeks of treatment or after dose changes. Close clinical monitoring is required.

Each tablet/capsule contains Imipramine (as hydrochloride or pamoate salt) as the active ingredient, along with pharmaceutically acceptable excipients such as binders, fillers, and coating agents.

Depram is a tricyclic antidepressant (TCA) first introduced in the late 1950s, one of the earliest agents in this class. It is available in immediate-release tablet form (hydrochloride salt) and, in some markets, as a sustained-release capsule (pamoate salt). Depram works primarily by inhibiting the reuptake of norepinephrine and serotonin in the central nervous system, thereby increasing their availability at nerve synapses and relieving depressive symptoms. It also has anticholinergic, antihistaminic, and alpha-adrenergic blocking properties, which account for many of its side effects.

Depram belongs to the tricyclic antidepressant (TCA) class of medications, specifically the dibenzazepine subgroup.

Imipramine is believed to act by inhibiting the neuronal reuptake of norepinephrine and serotonin at the presynaptic membrane, increasing their concentration in the synaptic cleft and enhancing neurotransmission. This mechanism is thought to underlie its antidepressant effect. Imipramine also exhibits significant anticholinergic (antimuscarinic), antihistaminic (H1), and alpha-1 adrenergic blocking activity, which contribute to its side-effect profile (dry mouth, sedation, orthostatic hypotension). The mechanism of benefit in nocturnal enuresis is not fully established but may involve anticholinergic bladder effects, altered sleep architecture, and mild antidiuretic activity. Imipramine is extensively metabolized in the liver via CYP2D6 and CYP1A2 to its active metabolite desipramine.

Depram is taken orally, typically once daily at bedtime for maintenance therapy or in divided doses when starting treatment, with or without food. Tablets/capsules should be swallowed whole and not crushed or chewed unless specifically directed. Do not stop taking Depram suddenly; dose should be tapered gradually under physician supervision.

Depram has several clinically significant drug interactions:

• MAO inhibitors: Concurrent use or use within 14 days of stopping an MAOI is contraindicated due to risk of serotonin syndrome, hyperpyrexia, seizures, and death.
• Other serotonergic drugs (SSRIs, triptans, tramadol, fentanyl, lithium, St. John's Wort): increased risk of serotonin syndrome when combined with Depram.
• CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine, cimetidine): may significantly increase Depram plasma levels, increasing risk of toxicity including cardiac effects; dose adjustment may be needed.
• Anticholinergic drugs: additive anticholinergic effects (dry mouth, urinary retention, constipation, blurred vision) when combined with Depram.
• CNS depressants and alcohol: additive sedation and CNS depression with Depram.
• Antihypertensives (guanethidine, clonidine): Depram may blunt the antihypertensive effect of these agents.
• Class 1A/1C antiarrhythmics and other QT-prolonging drugs: additive cardiac conduction effects when used with Depram; avoid combination where possible.

Common side effects of Depram include:

• Dry mouth, constipation, blurred vision (anticholinergic effects)
• Drowsiness/sedation
• Orthostatic hypotension and dizziness
• Tachycardia (increased heart rate)
• Weight gain
• Sweating
• Tremor

Less common but serious effects include cardiac conduction abnormalities and arrhythmias, seizures, urinary retention, and increased risk of suicidal thinking/behavior in younger patients (see Precautions and Warnings). If severe or persistent side effects occur while taking Depram, contact a physician promptly.

Depram does not have a well-established formal safety profile in pregnancy. Clinical reports of congenital malformations have been associated with use, though a causal relationship has not been definitively established. Depram should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use. Neonates exposed to Depram late in the third trimester have developed withdrawal-like symptoms. Depram is excreted in breast milk, and nursing mothers are generally advised not to take it unless a physician determines the benefit outweighs the risk to the infant; alternative feeding or medication should be discussed with a healthcare provider.

Depram requires caution in the following situations:

• Suicidality risk: as noted in the boxed warning, close monitoring is needed in children, adolescents, and young adults under 25, especially early in treatment.
• Cardiac disease: Depram can cause conduction abnormalities, arrhythmias, and QT prolongation; use with caution in patients with pre-existing cardiac disease, and obtain baseline ECG in older patients or those with cardiac risk factors.
• Narrow-angle glaucoma: anticholinergic effects of Depram can precipitate acute angle closure; use with caution.
• Urinary retention/benign prostatic hyperplasia: anticholinergic effects may worsen urinary retention.
• Seizure disorders: Depram lowers the seizure threshold; use cautiously in patients with a history of seizures.
• Elderly patients: increased sensitivity to anticholinergic and sedative effects, higher fall risk.
• Hyperthyroidism or thyroid medication use: may increase risk of cardiac arrhythmias.
• Abrupt discontinuation: may cause withdrawal symptoms (nausea, headache, malaise); taper gradually.

Overdose with Depram is particularly dangerous and can be life-threatening, primarily due to cardiotoxicity. Symptoms may include cardiac arrhythmias, severe hypotension, seizures, and CNS depression progressing to coma. Other signs include tachycardia, widened QRS complex, and respiratory depression. If overdose of Depram is suspected, seek emergency medical attention or contact a poison control center immediately — do not wait for symptoms to appear. Children may be especially sensitive to acute overdose. Management requires hospital-based cardiac monitoring and supportive care; this should only be carried out by medical professionals.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

Depram should be used at lower starting doses in elderly patients due to increased sensitivity to anticholinergic and cardiac side effects and higher fall risk.

Renal Impairment

Use with caution; Depram is primarily hepatically metabolized, but accumulation of metabolites may occur with significant renal impairment. Monitor closely.

Hepatic Impairment

Depram is extensively metabolized by the liver; use with caution and reduced doses in patients with hepatic impairment.

Children

Use of Depram for nocturnal enuresis is limited to children 6 years and older after organic causes are excluded; not recommended in children under 6. Safety and efficacy for depression in children under 6 have not been established.

For depression, Depram is typically continued for at least several months after symptom improvement to prevent relapse, with periodic reassessment by a physician. For nocturnal enuresis, Depram is intended for short-term adjunct use with periodic reassessment (e.g., every few months) to determine continued need; it is not intended for indefinite use in children.

Tricyclic antidepressant (TCA), dibenzazepine derivative.

Imipramine inhibits presynaptic reuptake of norepinephrine and serotonin, increasing their synaptic concentration and enhancing neurotransmission, which is believed to underlie its antidepressant effect. It also blocks muscarinic, histaminic (H1), and alpha-1 adrenergic receptors, contributing to its side effect profile.

Depram is approved for use in children 6 years of age and older as an adjunct in the treatment of nocturnal enuresis, only after organic causes have been ruled out, and only as a short-term measure with periodic reassessment. Safety and efficacy of Depram for depression in pediatric patients have not been established, and its use for depression in this age group is not recommended. All pediatric patients on Depram require close monitoring for suicidal thinking and behavior, per the boxed warning.